2024-09-23 - Analysis Report
##  Merck & Co. Inc. (MRK) Stock Analysis

**Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that researches, develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products. 

**1. Performance Analysis:**

* **Cumulative Return:** MRK has a cumulative return of 82.41% compared to the S&P 500 (VOO) with a cumulative return of 132.53%.
* **Relative Performance:** MRK lags behind the S&P 500 by 50.12%, ranking at the 33.52 percentile of its historical performance range.

**2. Recent Price Movement:**

* **Closing Price:** $117.17
* **Moving Averages:**
    * 5-day: $117.84
    * 20-day: $116.86
    * 60-day: $119.52 

**3. Technical Indicators:**

* **RSI:** 45.66 - This suggests that the stock is in a neutral territory. 
* **PPO:** 0.26 -  A positive PPO value indicates that the price is rising faster than the moving average.
* **Delta_Previous_Relative_Divergence:** -4.11 - This negative value suggests a recent short-term decline in relative performance.
* **Expected Return:** 15.04% - This represents the estimated potential return over the next 5 years.

**4. Recent Earnings and Outlook:**

| Date      | EPS    | Revenue        |
| --------- | ------ | --------------- |
| 2024-08-05 | 2.15   | $16.11 Billion |
| 2024-05-03 | 1.88   | $15.78 Billion |
| 2023-11-03 | 1.87   | $15.96 Billion |
| 2023-08-07 | -2.35  | $15.04 Billion |
| 2024-08-05 | -2.35  | $15.04 Billion |

* The most recent earnings report (2024-08-05) showed an EPS of $2.15, surpassing analysts' expectations.  Revenue also exceeded expectations at $16.11 Billion.

**5. Overall Analysis:**

MRK has lagged behind the broader market (S&P 500) in the past. However, recent earnings results have been positive, exceeding analysts' expectations. This, combined with a neutral RSI and a positive PPO, suggests potential upside in the near term. The recent short-term decline in relative performance needs to be monitored, but the overall technical indicators and strong earnings suggest a positive outlook. However, the company's future performance may be impacted by various factors like competition, regulatory changes, and economic conditions.

**6. Recommendations:**

Investors interested in pharmaceuticals and seeking long-term growth may find MRK appealing. The company's strong earnings and positive technical indicators suggest potential upside. However, investors should monitor the market, consider the potential risks, and conduct thorough research before making any investment decisions. 
